Table 23.
Hazards Ratios for Death and 95% Confidence Intervals for Age Group at Diagnosis, Sex, Race, and Ethnicity for Selected Primary Malignant Brain and Other CNS Tumor Histologies, CBTRUS Statistical Report: NPCR and SEER, 2001–2017
| Histology | N | Deaths | Age Groups (compared to children ages 0–14 yearsa) | Sex (compared to male) | Race & Ethnicity (Compared to White, Non-Hispanic) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AYAb (15–39) Years | Adults (40+) Years | Female | Black, Non-Hispanic | API, Non-Hispanic | AIAN, Non-Hispanic | Hispanic | ||||||||||
| HR (95% CI) | P-value | HR (95% CI) | P-value | HR (95% CI) | P-value | HR (95% CI) | P-value | HR (95% CI) | P-value | HR (95% CI) | P-value | HR (95% CI) | P-value | |||
| Diffuse astrocytoma | 23,128 | 12,665 | 1.84 (1.67–2.03) | <0.001 | 6.74 (6.14–7.39) | <0.001 | 0.97 (0.94–1.01) | 0.096 | 1.04 (0.97–1.12) | 0.227 | 0.90 (0.80–1.01) | 0.061 | 0.83 (0.67–1.04) | 0.102 | 0.81 (0.76–0.86) | <0.001 |
| Anaplastic astrocytoma | 16,441 | 11,434 | 0.38 (0.34–0.42) | <0.001 | 1.26 (1.15–1.38) | <0.001 | 0.97 (0.94–1.01) | 0.111 | 1.08 (1.01–1.17) | 0.035 | 0.84 (0.74–0.94) | 0.003 | 0.96 (0.75–1.23) | 0.756 | 0.82 (0.77–0.88) | <0.001 |
| Glioblastoma | 133,535 | 118,828 | 0.73 (0.68–0.78) | <0.001 | 1.76 (1.65–1.88) | <0.001 | 1.02 (1.01–1.04) | <0.001 | 0.93 (0.90–0.95) | <0.001 | 0.70 (0.68–0.73) | <0.001 | 1.00 (0.91–1.09) | 0.927 | 0.77 (0.76–0.79) | <0.001 |
| Oligodendroglioma | 11,122 | 3,340 | 3.24 (2.21–4.76) | <0.001 | 7.32 (5.01–10.71) | <0.001 | 0.88 (0.82–0.94) | <0.001 | 1.44 (1.25–1.65) | <0.001 | 0.78 (0.62–0.96) | 0.022 | 1.21 (0.80–1.84) | 0.374 | 0.77 (0.68–0.87) | <0.001 |
| Anaplastic oligodendroglioma | 4,998 | 2,334 | 0.76 (0.50–1.15) | 0.191 | 1.63 (1.08–2.46) | 0.021 | 0.90 (0.82–0.97) | 0.008 | 1.29 (1.09–1.52) | 0.003 | 0.83 (0.68–1.03) | 0.089 | 0.95 (0.55–1.64) | 0.861 | 0.78 (0.68–0.90) | <0.001 |
| Oligoastrocytic tumors | 6,756 | 3,237 | 1.69 (1.24–2.31) | <0.001 | 3.67 (2.69–5.00) | <0.001 | 0.93 (0.87–1.00) | 0.055 | 1.30 (1.13–1.50) | <0.001 | 0.90 (0.74–1.10) | 0.292 | 1.38 (0.94–2.02) | 0.098 | 0.88 (0.78–0.99) | 0.036 |
| Pilocytic astrocytoma | 14,222 | 1,062 | 1.69 (1.45–1.97) | <0.001 | 7.87 (6.81–9.10) | <0.001 | 0.86 (0.76–0.97) | 0.015 | 1.40 (1.17–1.69) | <0.001 | 0.98 (0.66–1.47) | 0.936 | 1.23 (0.64–2.38) | 0.535 | 1.14 (0.95–1.36) | 0.164 |
| Unique astrocytoma variants | 1,267 | 298 | 1.21 (0.87–1.68) | 0.256 | 4.30 (3.11–5.96) | <0.001 | 0.79 (0.63–0.99) | 0.043 | 0.87 (0.61–1.23) | 0.429 | 1.36 (0.78–2.39) | 0.282 | 1.70 (0.70–4.14) | 0.24 | 0.83 (0.58–1.17) | 0.276 |
| Ependymal tumors | 10,831 | 2,297 | 0.42 (0.37–0.48) | <0.001 | 0.88 (0.80–0.97) | 0.010 | 0.75 (0.69–0.82) | <0.001 | 1.26 (1.10–1.44) | <0.001 | 0.92 (0.71–1.18) | 0.493 | 1.01 (0.62–1.66) | 0.966 | 1.10 (0.98–1.23) | 0.120 |
| Glioma malignant, NOS | 18,803 | 8,935 | 0.76 (0.70–0.82) | <0.001 | 3.53 (3.35–3.71) | <0.001 | 1.02 (0.98–1.06) | 0.367 | 1.10 (1.03–1.17) | 0.006 | 0.94 (0.83–1.06) | 0.282 | 0.87 (0.65–1.16) | 0.332 | 1.02 (0.96–1.09) | 0.465 |
| Other neuroepithelial tumors | 169 | 52 | 2.63 (0.72–9.61) | 0.144 | ** | ** | 0.85 (0.46–1.55) | 0.588 | 0.60 (0.21–1.72) | 0.339 | 1.17 (0.36–3.83) | 0.791 | ** | ** | 0.66 (0.30–1.48) | 0.317 |
| Neuronal and mixed neuronal-glial Tumors | 2,304 | 732 | 1.39 (1.01–1.90) | 0.040 | 2.13 (1.60–2.83) | <0.001 | 0.79 (0.68–0.92) | 0.002 | 1.44 (1.14–1.83) | 0.002 | 1.02 (0.72–1.44) | 0.922 | 1.67 (0.74–3.75) | 0.217 | 1.10 (0.87–1.38) | 0.431 |
| Choroid plexus tumors | 351 | 135 | 0.72 (0.41–1.28) | 0.263 | 1.42 (0.91–2.22) | 0.123 | 0.91 (0.65–1.28) | 0.577 | 1.36 (0.81–2.28) | 0.248 | 1.13 (0.52–2.46) | 0.754 | 3.55 (1.25–10.08) | 0.018 | 0.62 (0.40–0.97) | 0.036 |
| Tumors of the pineal region | 1,016 | 357 | 0.72 (0.56–0.93) | 0.013 | 1.10 (0.85–1.43) | 0.481 | 0.74 (0.60–0.91) | 0.005 | 1.11 (0.86–1.43) | 0.442 | 0.51 (0.23–1.16) | 0.107 | 0.89 (0.28–2.79) | 0.836 | 1.02 (0.76–1.38) | 0.872 |
| Embryonal tumors | 9,854 | 3,819 | 0.83 (0.77–0.90) | <0.001 | 1.96 (1.79–2.16) | <0.001 | 1.00 (0.93–1.06) | 0.903 | 1.24 (1.12–1.37) | <0.001 | 1.08 (0.92–1.27) | 0.359 | 0.84 (0.56–1.27) | 0.41 | 0.96 (0.88–1.04) | 0.288 |
| Nerve sheath tumors | 664 | 233 | 1.54 (0.81–2.93) | 0.192 | 1.67 (0.90–3.10) | 0.106 | 0.76 (0.58–0.98) | 0.037 | 1.84 (1.27–2.68) | 0.001 | 0.15 (0.04–0.62) | 0.009 | ** | ** | 1.10 (0.73–1.64) | 0.652 |
| Meningiomas | 4,809 | 2,325 | 0.76 (0.43–1.33) | 0.334 | 2.41 (1.42–4.07) | 0.001 | 0.73 (0.67–0.79) | <0.001 | 0.93 (0.83–1.05) | 0.227 | 0.84 (0.68–1.05) | 0.130 | 0.81 (0.42–1.55) | 0.518 | 0.76 (0.65–0.89) | <0.001 |
| Mesenchymal tumors | 1,847 | 736 | 0.70 (0.51–0.95) | 0.022 | 1.51 (1.15–1.98) | 0.003 | 1.01 (0.87–1.17) | 0.882 | 1.10 (0.86–1.40) | 0.455 | 0.89 (0.63–1.26) | 0.510 | 1.54 (0.76–3.09) | 0.23 | 0.88 (0.71–1.10) | 0.259 |
| Primary melanocytic lesions | 158 | 118 | 0.35 (0.17–0.73) | 0.005 | 0.55 (0.30–1.00) | 0.049 | 0.88 (0.60–1.29) | 0.517 | 1.46 (0.58–3.72) | 0.423 | 0.98 (0.31–3.12) | 0.969 | ** | ** | 1.53 (0.89–2.61) | 0.124 |
| Lymphoma | 18,255 | 12,372 | 3.77 (2.60–5.46) | <0.001 | 7.00 (4.86–10.08) | <0.001 | 0.94 (0.91–0.97) | <0.001 | 1.14 (1.08–1.22) | <0.001 | 0.80 (0.73–0.87) | <0.001 | 1.07 (0.86–1.35) | 0.539 | 0.90 (0.85–0.96) | <0.001 |
| Other hematopoietic neoplasms | 223 | 101 | ** | ** | ** | ** | 1.10 (0.74–1.64) | 0.634 | 0.84 (0.51–1.38) | 0.500 | 1.19 (0.43–3.30) | 0.733 | 1.84 (0.44–7.64) | 0.402 | 0.66 (0.35–1.26) | 0.209 |
| Germ cell tumors | 2,921 | 437 | 1.04 (0.85–1.27) | 0.697 | 3.49 (2.43–5.01) | <0.001 | 1.54 (1.25–1.90) | <0.001 | 0.84 (0.59–1.20) | 0.345 | 1.02 (0.73–1.40) | 0.925 | 1.52 (0.56–4.09) | 0.408 | 1.12 (0.89–1.42) | 0.324 |
| Tumors of the pituitary | 401 | 134 | ** | ** | ** | ** | 0.75 (0.53–1.07) | 0.112 | 1.70 (1.12–2.57) | 0.012 | 0.58 (0.14–2.35) | 0.442 | ** | ** | 0.80 (0.44–1.44) | 0.453 |
| Neoplasm, unspecified | 10,172 | 8,281 | 0.68 (0.56–0.82) | <0.001 | 3.08 (2.63–3.60) | <0.001 | 1.05 (1.01–1.10) | 0.018 | 0.74 (0.68–0.80) | <0.001 | 0.81 (0.70–0.93) | 0.003 | 0.77 (0.57–1.03) | 0.075 | 0.70 (0.64–0.76) | <0.001 |
| All other | 173 | 96 | 0.69 (0.40–1.17) | 0.168 | 0.87 (0.48–1.60) | 0.660 | 0.75 (0.50–1.14) | 0.184 | 0.83 (0.39–1.74) | 0.618 | 1.08 (0.39–3.02) | 0.885 | 1.12 (0.27–4.63) | 0.879 | 0.94 (0.56–1.58) | 0.819 |
aChildren as defined by the National Cancer Institute, see: http://www.cancer.gov/researchandfunding/snapshots/pediatric.
bAdolescents and Young Adults (AYA), as defined by the National Cancer Institute, see: http://www.cancer.gov/cancertopics/aya.
** Cannot be calculated
Abbreviations: AYA, Adolescents and Young Adults; CBTRUS, Central Brain Tumor Registry of the United States; NPCR, National Program of Cancer Registries; SEER, Surveillance, Epidemiology, and End Results Program; CI, confidence interval; NOS, not otherwise specified